TYRA Stock — Tyra Biosciences Inc.: Cash, EV, Pipeline

Share price

$25.73

Market cap

$1,769.1M

Cash

$727.8M

Enterprise value

$1,041.3M

Balance sheet

Cash	$727.8M
Debt	$0.0M
Net cash	$727.8M
Enterprise value	$1,041.3M
Basic shares	59.7M shares
Fully diluted shares	82.0M shares
Fully diluted market cap	$2,109.8M
Cash per share	$12.19

Cash figures as of 2026-09-15. Database snapshot: 2026-09-21.

Price history

Loading TYRA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 13, 2026 - Jan 24, 2027	TYRA-300	Phase 2	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor	—
Feb 12 - Mar 25	TYRA-430	Phase 1	Metastatic Hepatocellular Carcinoma; Solid Tumors; Solid Tumor, Adult	—
Mar 14 - Apr 25	TYRA-300 60mg	Phase 2	Low-grade NMIBC; FGFR Gene Amplification; FGFR Gene Alterations	—
Nov 12 - Dec 24	Dabogratinib (TYRA-300) 60mg	Phase 2	Low Grade Upper Tract Urothelial Carcinoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

dabogratinib

Phase 2 · Active Modality: small molecule (oral; FGFR3-selective)

Target FGFR3

Indications

Low-grade upper tract urothelial carcinoma (LG-UTUC) (Phase 2)
Intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) (Phase 2)
Achondroplasia (children) (Phase 2)

Catalysts

— Sep 2026
— Q1 2027
— 2027

Status note 'Dabogratinib 3x3' strategy: three Phase 2 trials (SURF303, SURF302, BEACH301) toward three potential registrational trials.

TYRA-430

Phase 1 · Active Modality: small molecule (oral; FGFR4/FGFR3-biased)

Target FGFR4 / FGFR3

Indications

FGF19-positive hepatocellular carcinoma (Phase 1)

Status note SURF431 global Phase 1 open-label trial focused on clinical proof-of-concept in FGF19+ HCC.

TYRA-200

Phase 1 · Active Modality: small molecule (oral; FGFR1/2/3 inhibitor)

Target FGFR1 / FGFR2 / FGFR3

Indications

FGFR2-driven intrahepatic cholangiocarcinoma resistant to prior FGFR inhibitors (Phase 1)

Status note SURF201 global Phase 1 open-label trial; designed active against acquired pan-FGFR inhibitor resistance mutations.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TYRA-300
Lead indication	Locally Advanced Urothelial Carcinoma
Lead phase	Phase 2
Active trials	7

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05544552	Phase 2	Active, not recruiting	Sponsor	TYRA	—	Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Solid Tumor	—
NCT06995677	Phase 2	Recruiting	Sponsor	TYRA	—	Low-grade NMIBC; FGFR Gene Amplification; FGFR Gene Alterations	—
NCT06842355	Phase 2	Recruiting	Sponsor	TYRA	—	Achondroplasia	—
NCT07265947	Phase 2	Recruiting	Sponsor	TYRA	—	Low Grade Upper Tract Urothelial Carcinoma	—
NCT06915753	Phase 1	Recruiting	Sponsor	TYRA	—	Metastatic Hepatocellular Carcinoma; Solid Tumors; Solid Tumor, Adult	—
NCT06006702	Phase 1	Active, not recruiting	Sponsor	TYRA	—	Healthy	—
NCT06160752	Phase 1	Active, not recruiting	Sponsor	TYRA	—	Locally Advanced Cholangiocarcinoma; Intrahepatic Cholangiocarcinoma; Solid Tumor	—

Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 7 active trials for Tyra Biosciences, Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	102,000	+102,000	0.06%	2026-08-14
Baker Bros. Advisors	10,607	no change	0.00%	2026-08-14
Logos Global Management	0	-850,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

TYRA — Tyra Biosciences Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders